GABRA6

Across TCGA pan-cancer cohorts, GABRA6 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated GABRA6 data layer compared with 16 for mass-spec protein.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher GABRA6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GABRA6 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

PAAD, UCEC, and ACC are the cancer types where GABRA6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	OS	Median	All	0.136	0.616	<.001	30	view →
UCEC	DFS	Median	All	0.943	0.614	.008	22	view →
ACC	OS	Median	All	0.214	0.802	.002	15	view →
BLCA	OS	Median	All	0.199	0.692	.003	15	view →
LIHC	DFS	Median	II,III,IV	0.079	0.417	.001	15	view →
LGG	DFS	Median	All	0.083	0.826	<.001	6	view →
LUSC	DFS	Median	III,IV	0.079	0.751	.024	6	view →
GBM	DFS	Median	All	0.108	0.295	.046	3	view →
SKCM	DFS	Median	All	0.435	0.197	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

GABRA6–PAAD (OS)

Open the PAAD breakdown →